Please login to the form below

Not currently logged in
Email:
Password:

multiple melanoma

This page shows the latest multiple melanoma news and features for those working in and with pharma, biotech and healthcare.

BMS wins first US immuno-oncology paediatric licence

BMS wins first US immuno-oncology paediatric licence

BMS wins first US immuno-oncology paediatric licence. FDA gives the green light to expanded use of its melanoma treatment Yervoy. ... led analysts at EvaluatePharma to predict that Merck &Co’s melanoma drug Keytruda (pembrolizumab) will topple Opdivo

Latest news

  • BMS' Empliciti approved by FDA for multiple myeloma BMS' Empliciti approved by FDA for multiple myeloma

    BMS' Empliciti approved by FDA for multiple myeloma. Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone. ... The new therapies provide new options for patients with multiple myeloma, the second most common form of blood cancer.

  • Pfizer and Merck flesh out Xalkori alliance details Pfizer and Merck flesh out Xalkori alliance details

    BMS' Opdivo is used to treat melanoma and non-small cell lung cancer (NSCLC), with Merck's Keytruda (pembrolizumab) currently approved for melanoma only. ... Both drugs have multiple new indications coming through the pipeline, while additional

  • AB Science on track for phase III data in Alzheimer's this year AB Science on track for phase III data in Alzheimer's this year

    The drug is in trials for a host of cancer indications, including phase III studies in gastrointestinal stromal tumours (GIST), colorectal cancer, multiple myeloma and melanoma, as well as phase II ... Outside the cancer area it is being trialled in

  • GSK and Bayer strike new biotech cancer deals GSK and Bayer strike new biotech cancer deals

    It seems GSK still has interests in cancer, however, and will be looking to make the most of Adaptimmune's technology in cancer immunotherapies, which has shown promise in treating multiple ... myeloma, melanoma, sarcoma and ovarian cancer.

  • Prix Galien shortlist announced

    Myers Squibb's melanoma treatment Yervoy (ipilimumab); Novartis' oral multiple sclerosis treatment Gilenya (fingolimod); Roche's Zelboraf (vemurafenib) for melanoma; Shire's Resolor (prucalopride) for chronic constipation in women; and

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics